Literature DB >> 17112643

Comprehensive epitope analysis of cross-clade Gag-specific T-cell responses in individuals with early HIV-1 infection in the US epidemic.

Uma Malhotra1, Jessica Nolin, James I Mullins, M Juliana McElrath.   

Abstract

To elucidate the mechanisms underlying cross-clade T-cell reactivity, we evaluated responses to Gag peptides based on clades A, B, C, and M-group sequences at the epitope level by IFN-gamma ELISpot assay in 25 subjects following primary clade B infection. T-cell reactivity to CON (consensus), COT (center of tree), and ANC (most recent common ancestor) B peptides was similar and a high level of cross-reactivity was noted to clade A, C, and M-group peptides. T-cell responses to 15 of the 16 epitopes reacted with at least 1 of the 2 heterologous peptides (A or C or both) and 7 epitopes were invariant across all 3 clades. The remaining 9 epitopes were associated with a total of 11 variant sequences, and with the exception of 1, all substitutions were outside the HLA anchor positions. We conclude that Gag-specific cross-clade T-cell responses producing IFN-gamma can be detected in primary HIV-1 infection. Cross-reactivity is attributable to the recognized epitopes being either invariant across clades or differing by single amino acid substitutions outside the HLA anchor sites. Semi-conservative and non-conservative substitutions that presumably involve the T-cell receptor contact sites have significant effects on T-cell recognition. Finally, further studies are needed to determine if the detection of cross-clade IFN-gamma T-cell responses indeed translates to cross-reactive antiviral activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17112643     DOI: 10.1016/j.vaccine.2006.07.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Group testing for case identification with correlated responses.

Authors:  Samuel D Lendle; Michael G Hudgens; Bahjat F Qaqish
Journal:  Biometrics       Date:  2011-09-27       Impact factor: 2.571

2.  An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.

Authors:  Richard F Jones; Joyce D Reyes; Heather M Gibson; Jennifer B Jacob; Ulka Vaishampayan; Stuart Ratner; Kang Chen; Wei-Zen Wei
Journal:  Cancer Immunol Immunother       Date:  2019-06-08       Impact factor: 6.968

3.  HIV-1-specific enzyme-linked immunosorbent spot assay responses in HIV-1-exposed uninfected partners in discordant relationships compared to those in low-risk controls.

Authors:  Brandon L Guthrie; Barbara Lohman-Payne; Amy Y Liu; Rose Bosire; Samuel Victor Nuvor; Robert Y Choi; Romel D Mackelprang; James N Kiarie; Stephen C De Rosa; Barbra A Richardson; Grace C John-Stewart; Carey Farquhar
Journal:  Clin Vaccine Immunol       Date:  2012-09-12

4.  Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Authors:  Richard A Koup; Mario Roederer; Laurie Lamoreaux; Jennifer Fischer; Laura Novik; Martha C Nason; Brenda D Larkin; Mary E Enama; Julie E Ledgerwood; Robert T Bailer; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

5.  Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants.

Authors:  U Malhotra; J Nolin; H Horton; F Li; L Corey; J I Mullins; M J McElrath
Journal:  Vaccine       Date:  2009-09-09       Impact factor: 3.641

6.  Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants.

Authors:  Gabriela Turk; María Magdalena Gherardi; Natalia Laufer; Mónica Saracco; Renata Luzzi; Josephine H Cox; Pedro Cahn; Horacio Salomon
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

7.  Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection.

Authors:  Elena E Giorgi; Harikrishnan Balachandran; Mark Muldoon; Norman L Letvin; Barton F Haynes; Bette T Korber; Sampa Santra
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

8.  Unique CRF01_AE Gag CTL epitopes associated with lower HIV-viral load and delayed disease progression in a cohort of HIV-infected Thais.

Authors:  Masahiko Mori; Busarawan Sriwanthana; Nuanjun Wichukchinda; Chetsada Boonthimat; Naho Tsuchiya; Toshiyuki Miura; Panita Pathipvanich; Koya Ariyoshi; Pathom Sawanpanyalert
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

9.  HIV-1-Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection.

Authors:  Victor Y Du; Anju Bansal; Jonathan Carlson; Jesus F Salazar-Gonzalez; Maria G Salazar; Kristin Ladell; Stephanie Gras; Tracy M Josephs; Sonya L Heath; David A Price; Jamie Rossjohn; Eric Hunter; Paul A Goepfert
Journal:  J Immunol       Date:  2016-03-16       Impact factor: 5.422

10.  The effect of HLA polymorphisms on the recognition of Gag epitopes in HIV-1 CRF01_AE infection.

Authors:  Busarawan Sriwanthana; Masahiko Mori; Mari Tanaka; Sei Nishimura; Toshiyuki Miura; Panita Pathipvanich; Pathom Sawanpanyalert; Koya Ariyoshi
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.